Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records for Lixisenatide

23 records for Lixisenatide, of which 4 are published trials.

Showing 0 records on this page

Records

23 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
ELIXALixisenatidePhase 3ReportedEvent-driven cardiovascular outcome trial6,0682015High
ELIXA-DDIprogramme recordLixisenatidePhase 1ReportedRandomised crossover2015Very low
ELIXA-HEPATIC-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2015Very low
ELIXA-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2015Very low
ELIXA-PKprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2015Very low
GETGOAL-MLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled6802013High
GETGOAL-LLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled4952013High
GETGOAL-DUO-1LixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled4462013High
GETGOAL-M-BIOMARKERprogramme recordLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
GETGOAL-L-PKprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-DUO-1-HEPATIC-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-M-ADHERENCEprogramme recordLixisenatidePhase 3ReportedObservational2013Very low
GETGOAL-L-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-DUO-1-DDIprogramme recordLixisenatidePhase 1ReportedRandomised crossover2013Very low
GETGOAL-M-OLEprogramme recordLixisenatidePhase 3ReportedSingle-arm open-label2013Very low
GETGOAL-L-HEPATIC-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-DUO-1-PKprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-M-ELDERLYprogramme recordLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
GETGOAL-L-DDIprogramme recordLixisenatidePhase 1ReportedRandomised crossover2013Very low
GETGOAL-DUO-1-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-M-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose2013Very low
GETGOAL-L-BODY-COMPprogramme recordLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
GETGOAL-DUO-1-ELDERLYprogramme recordLixisenatidePhase 3ReportedRandomised, double-blind, placebo-controlled2013Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.